Skip to main content
. 2014 Nov 7;9(1):143–148. doi: 10.3892/ol.2014.2687

Figure 4.

Figure 4

A PI3K/Akt-GSK-3β-ZEB2 signaling pathway is involved in IGF-I-induced epithelial-to-mesenchymal transition. The serum-starved BGC-823 cells were pretreated with or without (A) PI3K/Akt inhibitor, LY294002 (100 μM) or (B) GSK-3β inhibitor, AR-A01448 (25 μM) for 2 h, followed by IGF-I (100 ng/ml) treatment for 48 h. Cell lysates were collected for western blot analysis. The images were analyzed using NIH Image software and presented as histograms. Data are presented as the mean ± standard deviation of three independent experiments. *IGF-I untreated vs. IGF-I treated, P<0.05. **IGF-I treated vs. LY or AR treated, p < 0.05. *** IGF-I treated vs. IGF-I combined with LY or AR, P<0.05. The control group was used as the reference. PI3K, phosphoinositide 3-kinase; IGF-I, insulin-like growth factor-I; GSK-3β, glycogen synthase kinase 3β; E-cad, E-cadherin; LY, LY294002; AR, AR-A01448.